Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chih-Yi Hsieh

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Journal of Colloid and Interface Science|July 14, 2009
Characterization of patterned poly(methyl methacrylate) brushes under various structures upon solvent immersionJem-Kun Chen, Chih-Yi Hsieh, Chih-Feng Huang, et al.
Cancer Medicine|September 13, 2022
Differences in sensitivity to new therapies between primary and metastatic breast cancer: A need to stratify the tumor response?Hubert Beaumont, Nathalie Faye, Antoine Iannessi, et al.
The Oncologist|June 20, 2023
Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I TrialJunning Cao, Hongqian Guo, Dongmei Ji, et al.
British Journal of Clinical Pharmacology|December 2, 2022
Effect of a strong CYP3A4 inhibitor and inducer on the pharmacokinetics of senaparib (IMP4297) in healthy volunteers: A drug-drug interaction studyXiaolei Hu, Chih-Yi Hsieh, Yanxin Zhang, et al.
Cancer|January 31, 2023
A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumorsBo Gao, Mark Voskoboynik, Adam Cooper, et al.
Therapeutic Advances in Hematology|March 14, 2018
Safety and efficacy of nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: results from the NOVEL studyChing-Yuan Kuo, Po-Nan Wang, Wen-Li Hwang, et al.
Nature Medicine|May 15, 2024
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trialXiaohua Wu, Jihong Liu, Jing Wang, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Journal of Colloid and Interface Science|July 14, 2009
Characterization of patterned poly(methyl methacrylate) brushes under various structures upon solvent immersionJem-Kun Chen, Chih-Yi Hsieh, Chih-Feng Huang, et al.
Cancer Medicine|September 13, 2022
Differences in sensitivity to new therapies between primary and metastatic breast cancer: A need to stratify the tumor response?Hubert Beaumont, Nathalie Faye, Antoine Iannessi, et al.
The Oncologist|June 20, 2023
Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I TrialJunning Cao, Hongqian Guo, Dongmei Ji, et al.
British Journal of Clinical Pharmacology|December 2, 2022
Effect of a strong CYP3A4 inhibitor and inducer on the pharmacokinetics of senaparib (IMP4297) in healthy volunteers: A drug-drug interaction studyXiaolei Hu, Chih-Yi Hsieh, Yanxin Zhang, et al.
Cancer|January 31, 2023
A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumorsBo Gao, Mark Voskoboynik, Adam Cooper, et al.
Therapeutic Advances in Hematology|March 14, 2018
Safety and efficacy of nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: results from the NOVEL studyChing-Yuan Kuo, Po-Nan Wang, Wen-Li Hwang, et al.
Nature Medicine|May 15, 2024
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trialXiaohua Wu, Jihong Liu, Jing Wang, et al.
Pageof 1